Table of Contents
Diagnostic and Therapeutic Endoscopy
Volume 1, Issue 2, Pages 75-78

Early Localization of Bronchogenic Carcinoma

1Cancer Imaging, British Columbia Cancer Research Centre and The University of British Columbia, Vancouver, B.C. V5Z 1L3, Canada
2Laboratory Medicine, British Columbia Cancer Agency, Vancouver, B.C. V5Z 4E6, Canada
3Department of Surgery, Tokyo Medical College Hospital, Tokyo, Japan
4Cancer Imaging, British Columbia Cancer Research Centre, 601 West 10th Avenue, Vancouver, B.C. V5Z 1L3, Canada

Received 4 April 1994; Accepted 20 May 1994

Copyright © 1994 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The performance of a fluorescence imaging device was compared with conventional white-light bronchoscopy in 100 patients with lung cancer, 46 patients with resected stage I non-small cell lung cancer, 10 patients with head and neck cancer, and 67 volunteers who had smoked at least 1 pack of cigarettes per day for 25 years or more. Using differences in tissue autofluorescence between premalignant, malignant, and normal tissues, fluorescence bronchoscopy was found to detect significantly more areas with moderate/severe dysplasia or carcinoma in situ than conventional white-light bronchoscopy with a similar specificity. Multiple foci of dysplasia or cancer were found in 13–24% of these individuals. Fluorescence bronchoscopy may be an important adjunct to conventional bronchoscopic examination to improve our ability to detect and localize premalignant and early lung cancer lesions.